Core Viewpoint - Huakang Clean (301235) announced that as of the date of the announcement, the company has no overdue guarantees, no litigation-related guarantees, and has not incurred losses due to guarantees, nor has it provided guarantees for its controlling shareholders, actual controllers, or their affiliates [1] Summary by Relevant Sections - Company Status - The company confirmed the absence of overdue guarantees [1] - There are no ongoing litigations related to guarantees [1] - The company has not been ordered to bear losses due to guarantee failures [1] - No guarantees have been provided for controlling shareholders or their affiliates [1]

武汉华康世纪洁净科技股份有限公司（以下简称"公司"）于 2025 年 4 月 24 日召开第二届董事会第二十二次会议、第二届监事会第二十一次会议，于 2025 年 5 月 16 日召开 2024 年年度股东大会，分别审议通过了《关于公司为子公司向 银行申请综合授信提供担保的议案》，同意公司为合并报表范围内的子公司湖北 菲戈特医疗科技有限公司、武汉光谷大健康医疗服务有限责任公司（以下简称"光 谷大健康"）申请银行综合授信额度提供不超过 70,000 万元（含本数）的连带 责任担保，担保额度在有效期内可以滚动使用，公司可在被担保对象间灵活调配 使用。上述授信额度及担保额度有效期自公司股东大会审议通过之日起十二个月 内。具体内容详见公司于 2025 年 4 月 25 日在中国证监会指定信息披露网站巨潮 资讯网披露的《关于公司为子公司向银行申请综合授信提供担保的公告》（公告 编号：2025-039）。 二、本次担保进展情况 证券代码：301235 证券简称：华康洁净 公告编号：2025-115 转债代码：123251 转债简称：华医转债 关于为子公司提供担保的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准 ...

证券代码：301235 证券简称：华康洁净 公告编号：2025-114 转债代码：123251 转债简称：华医转债 武汉华康世纪洁净科技股份有限公司 关于 2025 年第三季度可转换公司债券转股情况的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 特别提示： 1、华医转债（债券代码：123251）转股期限为 2025 年 6 月 27 日至 2030 年 12 月 22 日；最新有效的转股价格为人民币 22.43 元/股。 2、2025 年第三季度共有 486,482 张"华医转债"完成转股（票面金额共计 48,648,200 元人民币），共计转成 2,168,654 股"华康洁净"股票（证券代码： 301235）。 3、截至 2025 年第三季度末，公司剩余可转换公司债券张数为 7,013,428 张， 票面总金额为 701,342,800 元人民币。 根据《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司自 律监管指引第 15 号——可转换公司债券》的有关规定，武汉华康世纪洁净科技 股份有限公司（以下简称"公司"）现将 2025 年第三季度 ...

| 证券代码：301235 | 证券简称：华康洁净 | 公告编号：2025-113 | | --- | --- | --- | | 转债代码：123251 | 转债简称：华医转债 | | 武汉华康世纪洁净科技股份有限公司 关于股东减持至5%以下暨权益变动的提示性公告 公司股东阳光人寿保险股份有限公司保证向本公司提供的信息内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示： 一、本次权益变动的基本情况 （一）持股比例被动稀释 3、阳光人寿不属于公司控股股东、实际控制人及其一致行动人，本次权益变动不会导致公 司控股股东及实际控制人发生变化，不会对公司治理结构及持续经营产生重大影响。 经中国证券监督管理委员会《关于同意武汉华康世纪医疗股份有限公司向不特定对象发行可 转换公司债券注册的批复》(证监许可[2024]220号)同意注册，公司于2024年12月23日向不特定 对象发行可转换公司债券750万张，每张面值为100元，募集资金总额为人民币750,000,000.00元， 公司于2025年9月8日在巨潮资讯网披露了《关于持股5% ...

武汉华康世纪洁净科技股份有限公司 简式权益变动报告书 上市公司名称：武汉华康世纪洁净科技股份有限公司 股票上市地点：深圳证券交易所 股票简称：华康洁净 股票代码：301235 信息披露义务人：阳光人寿保险股份有限公司 住所/注册地址：海南省三亚市迎宾路 360-1 号三亚阳光金融广场 16 层 股份变动性质：股份数量减少、持股比例被动稀释（股权比例下降至 5%以下） 签署日期：2025 年 9 月 29 日 信息披露义务人声明 一、信息披露义务人依据《中华人民共和国证券法》（简称"《证券法》"） 《上市公司收购管理办法》（简称"《收购办法》"）《公开发行证券的公司信 息披露内容与格式准则第 15 号——权益变动报告书》及相关的法律、法规编制 本报告书。 二、信息披露义务人签署本报告书已获得必要的授权和批准。 三、依据《证券法》《收购办法》规定，本报告书已全面披露了信息披露义 务人在武汉华康世纪洁净科技股份有限公司（以下简称"华康洁净"或"公司"） 拥有权益的股份变动情况。截至本报告书签署之日，除本报告书披露的信息外， 信息披露义务人没有通过任何其他方式增加或减少其在华康洁净拥有权益的股 份。 四、本次权益变动 ...

Core Viewpoint - Huakang Clean achieved a significant increase in stock price and trading volume, indicating strong market interest and potential growth in the medical purification system sector [1][2]. Group 1: Financial Performance - For the first half of 2025, Huakang Clean reported revenue of 835 million yuan, representing a year-on-year growth of 50.73% [2]. - The net profit attributable to the parent company reached 18.68 million yuan, showing a substantial increase of 273.48% compared to the previous year [2]. - Cumulative cash dividends since the company's A-share listing amount to 40.02 million yuan, with 29.46 million yuan distributed over the past three years [3]. Group 2: Shareholder and Market Activity - As of September 19, the number of Huakang Clean's shareholders decreased by 2.96% to 10,000, while the average circulating shares per person increased by 3.05% to 7,272 shares [2]. - On September 25, Huakang Clean's financing buy-in amounted to 20.90 million yuan, with a net financing purchase of 1.18 million yuan, indicating strong investor interest [1]. - The total financing and securities balance reached 62.02 million yuan, accounting for 1.67% of the circulating market value, which is above the 90th percentile of the past year [1]. Group 3: Business Overview - Huakang Clean, established on November 12, 2008, specializes in the research, design, implementation, and operation of medical purification systems, along with the sale of related medical equipment and consumables [1]. - The revenue composition of Huakang Clean includes 85.24% from purification system integration, 8.53% from medical consumables, 3.74% from medical equipment sales, and 1.88% from operation services [1]. Group 4: Institutional Holdings - As of June 30, 2025, notable institutional shareholders include Anxin Medical Health Stock A, which is the fifth largest shareholder with 652,800 shares, and Nuoan Multi-Strategy Mixed A, the tenth largest shareholder with 429,900 shares, both being new entrants [3].

Group 1 - The core point of the article is that Huakang Clean (301235.SZ) has been awarded a contract for a medical purification project at Zhejiang Provincial Tumor Hospital Shaoxing Branch, which is expected to positively impact the company's future net profit [1] - The total amount of the project is approximately 136.27 million yuan, which represents 7.98% of the company's audited revenue for the year 2024 [1] - The execution of this project will not affect the company's business independence, and the formal contract signing and successful implementation are anticipated to yield positive financial results in the coming years [1]

Core Viewpoint - The company Huakang Clean (301235.SZ) has been awarded a contract for the medical purification special project at the Zhejiang Provincial Tumor Hospital Shaoxing Branch, confirming its role as the supplier for this significant construction project [1] Group 1: Project Details - The project involves the construction of a comprehensive tertiary hospital with a total building area of approximately 500,000 square meters and a total investment of around 5 billion [1] - The scope of the contract includes the procurement and installation of purification system facilities, covering various critical areas such as surgical ICUs, blood flow layer wards, and emergency testing departments [1] - The awarded contract value for the purification system special project is 136 million [1]

Core Viewpoint - The company Huakang Clean (301235.SZ) has been awarded a contract for the medical purification special project at the Zhejiang Provincial Tumor Hospital Shaoxing Branch, confirming its role as the supplier for this significant construction project [1] Group 1: Project Details - The project involves the construction of a comprehensive tertiary hospital with a total building area of approximately 500,000 square meters and a total investment of around 5 billion [1] - The scope of the contract includes the procurement and installation of purification system facilities, covering various critical areas such as surgical ICUs, blood flow layer wards, and emergency testing departments [1] - The awarded contract value for the purification system special project is 136 million [1]

Core Viewpoint - The company has won a bid for a medical purification project at the Zhejiang Provincial Cancer Hospital Shaoxing Branch, with a contract value of 136 million yuan, which represents 7.98% of the company's audited revenue for 2024 [1] Group 1 - The project involves the construction of a comprehensive tertiary hospital with a total building area of approximately 500,000 square meters and a total investment of around 5 billion yuan [1] - The company is responsible for the procurement and installation of purification system facilities for the project [1] - The execution of this project is expected to have a positive impact on the company's net profit in future years [1]